To reveal whether RAB9A promoted the malignant behavior of liver cancer cells by activating the AKT/mTOR signaling pathway, a double-effect inhibitor (BEZ235) which inhibits AKT and mTOR phosphorylation was used for complementation experiments. Here, RAB9A is linked to liver cancer.